In fact, the use of an Hsp90 inhibitor in the treatment of patients with psoriasis was discovered accidently during the first clinical trials of a new oral Hsp90 inhibitor (Debio 0932) in the treatment of oncological diseases, such as advanced solid tumors, lymphomas, and non-small cell lung cancer. This evidence concerns the gene HSP90AA1 and psoriasis.